PuSH - Publikationsserver des Helmholtz Zentrums München: SLAMF8 expression and prognostic significance in melanoma: A multi-omics and Mendelian randomization study.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Liu, J.* ; Han, W. ; Shen, G.*

SLAMF8 expression and prognostic significance in melanoma: A multi-omics and Mendelian randomization study.

Cancer Biomark. 42:18758592251392828 (2025)

Verlagsversion

DOI

PMC

	Open Access Hybrid

Abstract
Metriken
Zusatzinfos

BackgroundMelanoma represents one of the most aggressive skin cancers, responsible for over 75% of skin cancer-related deaths despite comprising only 5% of cases. Despite therapeutic advances, patient responses remain variable and unpredicv. The Signaling Lymphocytic Activation Molecule (SLAM) family regulates immune cell communication, with SLAMF8 being predominantly expressed on myeloid cells. However, SLAMF8's specific role in melanoma pathogenesis remains largely unexplored.MethodsIn this retrospective integrative study, we systematically investigated SLAMF8's role in melanoma through multi-omics analyses using TIMER, GEPIA, and UALCAN databases, following the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for observational data reporting. Functional studies were conducted in A-375 and SK-MEL-28 melanoma cell lines using siRNA-mediated knockdown, followed by migration, invasion, and proliferation assays. DNA methylation patterns were analyzed via the SMART database, while mutation profiles were examined using cBioPortal and COSMIC. Immune infiltration analysis was performed through TIMER, and pathway associations were investigated using Gene Set Enrichment Analysis and protein-protein interaction networks. Finally, two-sample Mendelian Randomization analysis assessed the causal relationship between SLAMF8 expression and melanoma susceptibility.ResultsSLAMF8 expression was significantly higher in metastatic melanoma compared to primary tumors, with expression patterns varying across disease stages and between sexes. Higher SLAMF8 expression correlated with improved disease-free and overall survival. Functional studies demonstrated that SLAMF8 knockdown significantly enhanced melanoma cell proliferation, migration, and invasion. DNA methylation analysis revealed significant negative correlations between methylation at specific CpG sites and SLAMF8 expression, with hypermethylation associated with worse survival outcomes. Mutation analysis identified alterations in 10.21% of melanoma patients. Immune infiltration studies demonstrated strong correlations between SLAMF8 expression and enhanced immune cell presence. GSEA linked SLAMF8 to critical immune pathways including allograft rejection, inflammatory response, and interferon signaling. Mendelian Randomization analysis established a protective causal relationship between SLAMF8 and melanoma risk (OR = 0.39, 95% CI = 0.21-0.74, p = 3.34e-03).ConclusionOur study demonstrates that SLAMF8 plays a critical role in melanoma by suppressing tumor progression and modulating the immune microenvironment. Elevated SLAMF8 expression in metastatic melanoma is associated with improved patient survival, suggesting its utility as a prognostic biomarker. Furthermore, its tumor-suppressive effects and immune-regulatory functions highlight SLAMF8 as a promising therapeutic target for melanoma treatment strategies.

Impact Factor

Scopus SNIP

Altmetric

0.000